A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase IV
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Umeclidinium/vilanterol (Primary) ; Salmeterol; Umeclidinium
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Jul 2017 Planned End Date changed from 27 Jun 2018 to 11 Jul 2018.
- 06 Jul 2017 Planned primary completion date changed from 27 Jun 2018 to 11 Jul 2018.
- 29 Jun 2017 Planned End Date changed from 11 Jul 2018 to 27 Jun 2018.